Ankylosing spondylitis (Morbus Bechterew) is the most prevalent spondyloarthropathy affecting 0.1-1% of the general population Symptoms at the onset of the disease are usually nonspecific, posing difficulties for a firm diagnosis. Differentiating between HLA-B27 positive and negative patients is therefore an important parameter for diagnosing spondyloarthropathies.
- Simple protocol for complex diagnostic questions
- Manual or automated
- No expensive lab equipment required
- Ready-to-use reagents
- Complete CE-certified kit – includes DNA extraction
The three steps of the ViennaLab HLA-B27 StripAssay® HLA-B, as part of the major histocompatibility complex (MHC) class I, is involved in the recognition of self and foreign peptides. The allelic variant HLA-B27 is present in about 8% of healthy Caucasians and is well known as genetic risk factor for spondyloarthropathies.
Up to 96% of patients with ankylosing spondylitis (Morbus Bechterew) and up to 80% of patients with reactive arthritis carry the HLAB27 allele. Ankylosing spondylitis is a chronic, inflammatory arthritis that mainly affects spinal joints and the sacroiliac joint. Patients suffer from chronic pain and stiffness in the back and pelvis and, with progressing disease, often develop spinal fusion. The disease usually manifests between 15-30 years of age and is three times more prevalent in males than in females. Often a time period of 5-10 years elapses between early, nonspecific symptoms and a definite diagnosis.
The HLA-B27 StripAssay detects all currently known HLA-B27 subtypes (B*2701 to B*2786), except for a few, very rare and disease-unrelated alleles (B*270509, B*2712, B*2716, B*2718, B*2723, B*2726, B*2729, B*2731, B*2777 and B*2785).
|HLA-B27 StripAssay®||4-320||20 Tests||Detection of all disease-relevant HLA-B27 subtypes|
|HLA-B27 RT-PCR Assay||7-620||100 Assays||Detection of most common mutations|